Assessment of In Silico and In Vitro Selpercatinib Metabolic Stability in Human Liver Microsomes Using a Validated LC-MS/MS Method

• Published in: Molecules (Basel, Switzerland) Switzerland), 2023-03, Vol.28 (6), p.2618
• Main Authors: Attwa, Mohamed W, AlRabiah, Haitham, Mostafa, Gamal A E, Bakheit, Ahmed H, Kadi, Adnan A
• Format: Article
• Language: English
• Subjects: Accuracy; Adult; Bioavailability; Brand names; Calibration; Chromatography; Chromatography, Liquid - methods; Clearances; Coefficient of variation; Guidelines; Humans; in vitro half-life; intrinsic clearance; Kinases; LC-MS/MS; Linearity; Liquid chromatography; Literature reviews; Liver; Mass spectrometry; Mass spectroscopy; metabolic stability; Metabolism; Metastases; Metastasis; Methods; Microsomes; Microsomes, Liver - metabolism; Mutation; Pyrazoles - metabolism; Quadrupoles; Reproducibility of Results; Ret protein; selpercatinib; Signal transduction; Software; Solid tumors; Stability analysis; Stationary phase; Tandem Mass Spectrometry - methods; Thyroid cancer; Transfection; Tumors; WhichP450 module
• ISSN: 1420-3049; 1420-3049
• DOI: 10.3390/molecules28062618

Selpercatinib (SLP; brand name Retevmo ) is a selective and potent RE arranged during transfection (RET) inhibitor. On 21 September 2022, the FDA granted regular approval to SLP (Retevmo, Eli Lilly, and Company). It is considered the only and first RET inhibitor for adults with metastatic or locally advanced solid tumors with RET gene fusion. In the current experiment, a highly specific, sensitive, and fast liquid chromatography tandem mass spectrometry (LC-MS/MS) method for quantifying SLP in human liver microsomes (HLMs) was developed and applied to the metabolic stability evaluation of SLP. The LC-MS/MS method was validated following the bioanalytical methodology validation guidelines outlined by the FDA (linearity, selectivity, matrix effect, accuracy, precision, carryover, and extraction recovery). SLP was detected by a triple quadrupole detector (TQD) using a positive ESI source and multiple reaction monitoring (MRM) mode for mass spectrometric analysis and estimation of analytes ions. The IS-normalized matrix effect and extraction recovery were acceptable according to the FDA guidelines for the bioanalysis of SLP. The SLP calibration standards were linear from 1 to 3000 ng/mL HLMs matrix, with a regression equation (y = 1.7298x + 3.62941) and coefficient of variation (r = 0.9949). The intra-batch and inter-batch precision and accuracy of the developed LC-MS/MS method were -6.56-5.22% and 5.08-3.15%, respectively. SLP and filgotinib (FLG) (internal standard; IS) were chromatographically separated using a Luna 3 µm PFP (2) stationary phase (150 × 4.6 mm) with an isocratic mobile phase at 23 ± 1 °C. The limit of quantification (LOQ) was 0.78 ng/mL, revealing the LC-MS/MS method sensitivity. The intrinsic clearance and in vitro t (metabolic stability) of SLP in the HLMs matrix were 34 mL/min/kg and 23.82 min, respectively, which proposed an intermediate metabolic clearance rate of SLP, confirming the great value of this type of kinetic experiment for more accurate metabolic stability predictions. The literature review approved that the established LC-MS/MS method is the first developed and reported method for quantifying SLP metabolic stability.